Work

Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.3000

Authors: Crystal Mackall, William D. Tap, John Glod, Mihaela Druta, Warren Allen Chow, Dejka M. Araujo, Stephan A. Grupp, Brian Andrew Van Tine, Karen Chagin, Erin Van Winkle, Gabor Kari, Trupti Trivedi, Elliot Norry, Tom Holdich, Arundathy N. Bartlett-Pandite, Rafael G. Amado, Sandra P. D'Angelo

Institutions: Stanford Medicine, Stanford University, Memorial Sloan Kettering Cancer Center, National Institutes of Health, National Cancer Institute, Moffitt Cancer Center, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Children's Hospital of Philadelphia, Washington University in St. Louis, Adaptimmune (United Kingdom)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2805477550

Cites:

Cited by: 20

Related to: 10